Tecan Resolvex for University of Utah

犹他大学 Tecan Resolvex

• 批准号: 10734678
• 负责人: JAMES Eric COX
• 金额: $ 5.69万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10734678
• 关键词: Academia; American; Biological; Chemicals; Devices; Diabetes Mellitus; Ensure; Foundations; Funding; Funding Agency; Grant; Human; Industry; Institution; Lipids; Liquid substance; Manuals; Mass Spectrum Analysis; Methodology; Methods; Modernization; Pesticides; Pharmaceutical Preparations; Phase; Preparation; Process; Request for Proposals; Research Personnel; Sampling; Services; Solid; Solvents; Technology; Time; Tracer; United States Department of Agriculture; United States National Institutes of Health; Universities; Utah; Work; data quality; human error; lipidomics; metabolomics; pressure

Project Summary / Abstract This proposal requests funding for a Tecan Resolvex A200 (Resolvex) to the Metabolomics Core (Core) for two primary purposes, to: 1) increase sample processing throughput, and 2) decrease human sample processing error. The Core provides a wide array of mass spectrometry-based services including metabolomics, lipidomics, flux tracer analysis, and targeted metabolite/drug quantitation. Over the past four fiscal years, the Core has served an average of 53 Principle Investigators (PI) per year, 40 PI’s from 20 departments at the University of Utah (UU) and an average of 13 users from outside academic institutions. The Core only tracks funding sources from UU researchers with an average of 23 NIH grants served per year. Other major funding sources include the American Diabetes Association, DOD, HHMI, JDRF, NSF, USDA as well as other foundation grants. The Core currently process approximately 10,000 samples a year, with most extractions performed manually using liquid/liquid extraction methods. This work is tedious, low throughput and prone to human error. Solid phase extraction (SPE) methodology has long standing in both academia and industry for the extraction of drugs and pesticides from biological matrixes. Recently, several technologies that use SPE for metabolomics and lipidomics have been introduced by Agilent. These technologies serve two functions, 1) they remove interfering chemical entities from a sample matrix, and 2) due to their 96-well format, increase sample through put. In order to meet the ever-increasing demand for Core services, a high throughput modernization plan is necessary. The Resolvex is central to this, it is needed to perform automated sample wash and elution steps from 96-well SPE plates by the precise addition of solvents to each well. The positive pressure mechanism used to elute solvents from each well ensures uniform sample preparation. Without this device, it is very difficult to leverage all the advantages provided by these new SPE technologies. The Resolvex is central to the modernization plan of the Core and will immediately make an impact in both sample throughput and data quality. It will be immediately used for the extraction and purification of both metabolites and lipids. In addition, by limiting the human error associated by manual pipetting, it will make a considerable difference in data quality.

项目概要/摘要 该提案请求为代谢组学核心 (Core) 的 Tecan Resolvex A200 (Resolvex) 提供资金 两个主要目的：1) 提高样本处理通量，2) 减少人类样本 处理错误。 Core 提供广泛的基于质谱的服务，包括代谢组学、脂质组学、通量 示踪剂分析和目标代谢物/药物定量。在过去的四个财年中，核心服务 每年平均有 53 名首席研究员 (PI)，其中 40 名 PI 来自犹他大学 20 个系 (UU)，平均有 13 位来自外部学术机构的用户。核心仅跟踪资金来源 来自 UU 研究人员，平均每年获得 23 项 NIH 资助。其他主要资金来源包括 美国糖尿病协会、DOD、HHMI、JDRF、NSF、USDA 以及其他基金会的资助。这 Core 目前每年处理大约 10,000 个样本，其中大多数提取使用手动执行 液/液萃取方法。这项工作繁琐、吞吐量低且容易出现人为错误。 固相萃取 (SPE) 方法在学术界和工业界长期以来一直用于萃取 从生物基质中提取药物和农药。最近，一些使用 SPE 的技术 安捷伦推出了代谢组学和脂质组学。这些技术有两个功能，1）它们 从样品基质中去除干扰化学实体，2) 由于其 96 孔格式，增加样品 通过放。为了满足对核心服务不断增长的需求，高吞吐量现代化 计划是必要的。 Resolvex 是其中的核心，需要它来执行自动样品清洗和洗脱 通过向每个孔中精确添加溶剂，从 96 孔 SPE 板开始进行步骤。正压 用于从每个孔中洗脱溶剂的机制确保了样品制备的均匀性。如果没有这个装置的话 很难利用这些新 SPE 技术提供的所有优势。 Resolvex 是核心现代化计划的核心，并将立即对这两个方面产生影响 样本吞吐量和数据质量。它将立即用于两者的提取和纯化 代谢物和脂质。此外，通过限制手动移液相关的人为错误，它将使得 数据质量差异较大。